TapewireFind a company

person · Reporting owner

Duarte Ira

Disclosed activity across 2 companies

Tapewire entity
27347
SEC CIK
0001488864

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133EVP, Chief Financial OfficerJuly 30, 2026August 03, 2026
TerrAscend Corp.TSNDF · Entity 6184DirectorJune 24, 2025June 25, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HERON THERAPEUTICS, INC. /DE/

Report date July 30, 2026 · Filed August 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect281,899 Ending reported balance After 2026-07-31 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2026-07-30 · Exercise / conversion · Acquired 13,535 · Balance 277,381

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

Row 2 · 2026-07-30 · Tax withholding · Disposed 3,850 · Balance 273,531

Row 3 · 2026-07-31 · Exercise / conversion · Acquired 11,694 · Balance 285,225

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

Row 4 · 2026-07-31 · Tax withholding · Disposed 3,326 · Balance 281,899

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct189,492 Reported balance After 2026-07-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-07-30 · Exercise / conversion · Disposed 13,535 · Balance 189,492

F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct116,944 Reported balance After 2026-07-31 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-07-31 · Exercise / conversion · Disposed 11,694 · Balance 116,944

F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

TerrAscend Corp.

Report date June 24, 2025 · Filed June 25, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect657,930 Reported balance After 2025-06-24 transaction · row 1
1 source row

Row 1 · 2025-06-24 · Grant · Acquired 433,653 · Balance 657,930

F1: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 31, 2026 Filed Aug 3, 2026 13:50 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 11,694 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-329720 · ownership.xml · derivative · entry 6

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,944

Underlying: Common Stock · 11,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
July 31, 2026 Filed Aug 3, 2026 13:50 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 3,326 $0.50 $1,663.00
Disclosure

SEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 4

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,899

Read SEC document
July 31, 2026 Filed Aug 3, 2026 13:50 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 11,694 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 3

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 285,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
July 30, 2026 Filed Aug 3, 2026 13:50 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 13,535 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-329720 · ownership.xml · derivative · entry 5

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,492

Underlying: Common Stock · 13,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

F2 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Read SEC document
July 30, 2026 Filed Aug 3, 2026 13:50 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 3,850 $0.50 $1,925.00
Disclosure

SEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,531

Read SEC document
July 30, 2026 Filed Aug 3, 2026 13:50 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 13,535 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-329720 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
July 19, 2026 Filed Jul 20, 2026 19:54 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,874 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-308887 · ownership.xml · derivative · entry 3

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,246

Underlying: Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
July 19, 2026 Filed Jul 20, 2026 19:54 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 1,101 $0.47 $517.47
Disclosure

SEC source: 0001193125-26-308887 · ownership.xml · nonDerivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,846

Read SEC document
July 19, 2026 Filed Jul 20, 2026 19:54 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,874 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-308887 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 16, 2026 Filed Jun 17, 2026 14:52 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-273552 · ownership.xml · derivative · entry 3

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Read SEC document
June 16, 2026 Filed Jun 17, 2026 14:52 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Tax withholdingCommon Stock 3,555 $0.38 $1,350.90
Disclosure

SEC source: 0001193125-26-273552 · ownership.xml · nonDerivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 261,073

Read SEC document
June 16, 2026 Filed Jun 17, 2026 14:52 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-273552 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 264,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 30, 2026 Filed May 4, 2026 15:56 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 13,535 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-203272 · ownership.xml · derivative · entry 4

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,027

Underlying: Common Stock · 13,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

F4 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

Read SEC document
April 30, 2026 Filed May 4, 2026 15:56 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 11,694 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-203272 · ownership.xml · derivative · entry 3

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,638

Underlying: Common Stock · 11,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
April 30, 2026 Filed May 4, 2026 15:56 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 13,535 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-203272 · ownership.xml · nonDerivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · balance_after: Includes 11,023 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2026.

Read SEC document
April 30, 2026 Filed May 4, 2026 15:56 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 11,694 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-203272 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,570

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 19, 2026 Filed Apr 21, 2026 13:13 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,874 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-165304 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,120

Underlying: Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
April 19, 2026 Filed Apr 21, 2026 13:13 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,874 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-165304 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,876

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · balance_after: Includes 16,646 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 13:30 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 11,695 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034492 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,332

Underlying: Common Stock · 11,695 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
January 31, 2026 Filed Feb 3, 2026 13:30 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 11,695 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-034492 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,356

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 15:00 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantPerformance Stock Units · Derivative 216,561 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034630 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,561

Underlying: Common Stock · 216,561 shares

Expires not disclosed

F3 · derivative.exercise_price: Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: On January 30, 2026, the Reporting Person was granted 216,561 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.

F4 · derivative.expiration_date: On January 30, 2026, the Reporting Person was granted 216,561 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.

Read SEC document
January 30, 2026 Filed Feb 3, 2026 15:00 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantRestricted Stock Units · Derivative 216,562 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034630 · ownership.xml · derivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 216,562

Underlying: Common Stock · 216,562 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.

F2 · derivative.expiration_date: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.

Read SEC document
January 19, 2026 Filed Jan 20, 2026 19:49 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,875 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-016423 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,994

Underlying: Common Stock · 3,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
January 19, 2026 Filed Jan 20, 2026 19:49 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-016423 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,661

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
October 31, 2025 Filed Nov 4, 2025 17:33 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 11,694 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-25-264039 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,027

Underlying: Common Stock · 11,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
October 31, 2025 Filed Nov 4, 2025 17:33 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 11,694 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-264039 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,786

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
October 19, 2025 Filed Oct 21, 2025 15:42 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,874 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-25-244560 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,869

Underlying: Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
October 19, 2025 Filed Oct 21, 2025 15:42 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,874 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-244560 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
July 31, 2025 Filed Aug 4, 2025 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 11,695 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-102158 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,721

Underlying: Common Stock · 11,695 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: The number of restricted stock units disclosed on the Reporting Person's Form 4 filed on April 22, 2025, May 2, 2025 and June 17 , 2025 ("Affected Form 4 Filings") were erroneously disclosed as an acquisition in Column 5(A) when it should have been disclosed as a disposition in Column 5(D). All other information in the Affected Form 4 Filings is correct.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
July 31, 2025 Filed Aug 4, 2025 21:27 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 11,695 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-102158 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
July 19, 2025 Filed Jul 22, 2025 16:23 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,874 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-097498 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,743

Underlying: Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
July 19, 2025 Filed Jul 22, 2025 16:23 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,874 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-097498 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,523

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 24, 2025 Filed Jun 25, 2025 20:55 UTC TerrAscend Corp. TSNDF · Entity 6184 GrantCommon Shares 433,653 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-018193 · form4-06252025_080616.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 657,930

F1 · shares: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2025, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.

Read SEC document
June 16, 2025 Filed Jun 17, 2025 21:53 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-087534 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Read SEC document
June 16, 2025 Filed Jun 17, 2025 21:53 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 12,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-087534 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,649

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 30, 2025 Filed May 3, 2025 00:32 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 11,694 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-063063 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,416

Underlying: Common Stock · 11,694 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
April 30, 2025 Filed May 3, 2025 00:32 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 11,694 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-063063 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,149

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 19, 2025 Filed Apr 22, 2025 13:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,875 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-056492 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,617

Underlying: Common Stock · 3,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
April 19, 2025 Filed Apr 22, 2025 13:57 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,875 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-056492 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,455

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
January 31, 2025 Filed Feb 4, 2025 17:44 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantRestricted Stock Units · Derivative 187,110 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-013044 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,110

Underlying: Common Stock · 187,110 shares

Expires not disclosed

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Read SEC document
January 31, 2025 Filed Feb 4, 2025 17:44 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 GrantEmployee Stock Option (Right to Buy) · Derivative 374,220 $0.00 Strike: $1.70 $0.00
Disclosure

SEC source: 0000950170-25-013044 · ownership.xml · derivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,220

Underlying: Common Stock · 374,220 shares

Expires 2035-01-31

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (January 31, 2025).

Read SEC document
January 19, 2025 Filed Jan 22, 2025 14:32 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,874 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-007557 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,492

Underlying: Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F3 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
January 19, 2025 Filed Jan 22, 2025 14:32 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,874 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-007557 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,580

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · balance_after: Includes 8,705 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2024.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 21:04 UTC TerrAscend Corp. TSNDF · Entity 6184 Tax withholdingCommon Shares 71,704 $0.65 $46,607.60
Disclosure

SEC source: 0001415889-25-000381 · form4-01032025_090143.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,277

F1 · shares: Shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted share units pursuant to an equity plan administered by the Issuer.

Read SEC document
October 19, 2024 Filed Oct 21, 2024 19:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,874 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-24-115927 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,366

Underlying: Common Stock · 3,874 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
October 19, 2024 Filed Oct 21, 2024 19:55 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,874 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-115927 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,001

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
July 19, 2024 Filed Jul 22, 2024 13:32 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 3,875 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-24-085089 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,240

Underlying: Common Stock · 3,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024).

Read SEC document
July 19, 2024 Filed Jul 22, 2024 13:32 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionCommon Stock 3,875 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-085089 · ownership.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,127

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 17, 2024 Filed Jun 20, 2024 21:30 UTC TerrAscend Corp. TSNDF · Entity 6184 GrantCommon Shares 163,334 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-017689 · form4-06202024_050608.xml · nonDerivative · entry 1

Duarte Ira · CIK 0001488864 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,981

F1 · shares: These shares represent a restricted share unit ("RSU") award for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2024, subject to the Reporting Person's continuous service with the Issuer as of the vesting date.

Read SEC document
June 16, 2024 Filed Jun 17, 2024 18:21 UTC HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 Exercise / conversionRestricted Stock Units · Derivative 12,500 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-24-074168 · ownership.xml · derivative · entry 2

Duarte Ira · CIK 0001488864 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 12,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.